Skip to Main Content

Paper Details

Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design.
Rheumatology (Oxford)
11
2021
Author NameAffiliation
Stephen R WisniewskiDivision of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine.
  • 1 - 1

Datasets

Release 1.2